Acadian Asset Management LLC Sells 73,456 Shares of Align Technology, Inc. $ALGN

Acadian Asset Management LLC lowered its stake in Align Technology, Inc. (NASDAQ:ALGN) by 57.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,712 shares of the medical equipment provider’s stock after selling 73,456 shares during the period. Acadian Asset Management LLC owned 0.07% of Align Technology worth $10,166,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Align Technology by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,441,592 shares of the medical equipment provider’s stock valued at $1,341,031,000 after purchasing an additional 185,187 shares in the last quarter. Invesco Ltd. lifted its holdings in Align Technology by 12.7% in the first quarter. Invesco Ltd. now owns 1,219,715 shares of the medical equipment provider’s stock worth $193,764,000 after buying an additional 137,553 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Align Technology by 32.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock valued at $132,221,000 after acquiring an additional 202,616 shares in the last quarter. Navera Investment Management Ltd. grew its holdings in shares of Align Technology by 3.0% during the 2nd quarter. Navera Investment Management Ltd. now owns 787,559 shares of the medical equipment provider’s stock worth $149,126,000 after acquiring an additional 23,080 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Align Technology by 0.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 736,635 shares of the medical equipment provider’s stock worth $117,022,000 after acquiring an additional 4,789 shares during the period. 88.43% of the stock is currently owned by institutional investors.

Align Technology Stock Up 4.5%

ALGN opened at $144.49 on Wednesday. The stock’s fifty day moving average is $132.67 and its two-hundred day moving average is $159.84. The company has a market capitalization of $10.37 billion, a P/E ratio of 28.00, a PEG ratio of 1.49 and a beta of 1.84. Align Technology, Inc. has a 52 week low of $122.00 and a 52 week high of $246.19.

Align Technology (NASDAQ:ALGN) last issued its earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.23. The company had revenue of $995.69 million for the quarter, compared to analysts’ expectations of $980.75 million. Align Technology had a net margin of 9.50% and a return on equity of 14.06%. The firm’s quarterly revenue was up 1.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.35 EPS. Align Technology has set its Q4 2025 guidance at EPS. Equities analysts anticipate that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology announced that its board has authorized a share repurchase plan on Tuesday, August 5th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

ALGN has been the subject of several recent research reports. Wall Street Zen upgraded shares of Align Technology from a “hold” rating to a “buy” rating in a report on Saturday. Evercore ISI increased their price objective on shares of Align Technology from $160.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. UBS Group dropped their price objective on shares of Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Thursday, October 16th. Needham & Company LLC reissued a “hold” rating on shares of Align Technology in a report on Thursday, October 30th. Finally, Zacks Research upgraded Align Technology from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $175.45.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.